Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where A. Gökhan Özgen is active.

Publication


Featured researches published by A. Gökhan Özgen.


Journal of Endocrinological Investigation | 2007

Demographic and clinical features of patients with subacute thyroiditis: Results of 169 patients from a single University Center in Turkey

Nihat Erdem; Mehmet Erdogan; M. Ozbek; Muammer Karadeniz; Sevki Cetinkalp; A. Gökhan Özgen; Fusun Saygili; C. Yilmaz; Mehmet Tüzün; Taylan Kabalak

Background: Turkey is an endemic area for thyroid diseases. The Aegean region is well documented for increased prevalence of thyroid disorders. In this study we investigated the demographic and clinical features of subacute thyroiditis (SAT) patients who had been diagnosed and treated in Ege University. Methods: The hospital files of patients admitted to the endocrinology clinic of Ege University between January 1987 and December 2001 were retrospectively evaluated. Patients who had been diagnosed as having any thyroid disorder were determined. Results: 176 fulfilled diagnostic criteria for SAT. The majority of patients with SAT were diagnosed as having subacute granulomatous thyroiditis (169/176) (134 females, 35 males, mean age 34.0±17.8 yr); 69% of the patients were between 30–50 yr of age. Thyroid pain was present in 97.1% of female patients, and in 100% of male patients. High fever was evident in 78 patients (46.2%). Mean erythrocyte sedimentation rate (ESR) was 43.42±39.68 mm/h. Anti-thyroglobulin antibody was positive in 20%, and anti-thyroid peroxydase antibody was positive in 4% of patients. Among patients who were treated with non-steroidal anti-inflammatory drugs (NSAD) 10 female patients (10.6%), and 3 male patients (12%) developed recurrence of the disease. Among patients who were treated with prednisolone 7 female patients (17.5%), and one male patient (10%) developed recurrence. There was no significant difference regarding the recurrence rates between patients who were treated with NSAD and patients who were treated with prednisolone. Conclusion: With the exception of ESR, demographic, clinical, laboratory, and imaging findings and prognoses of our patients were comparable to the previous reports.


Eating and Weight Disorders-studies on Anorexia Bulimia and Obesity | 1998

Long-term treatment with acarbose for the treatment of reactive hypoglycemia

A. Gökhan Özgen; Füsun Hamulu; Firat Bayraktar; Sevki Cetinkalp; C. Yilmaz; Mehmet Tüzün; Taylan Kabalak

Objective: Acarbose, a potent alpha-glucosidase inhibitor, provides a new concept for the treatment of metabolic disorders, and particularly diabetes mellitus. It reduces the postprandial blood glucose increment and insulin response. For this reason the drug has been successfully used not only in the treatment of type 1 and type 2 diabetes, but also in the management of reactive hypoglycemia and dumping syndrome. The primary aim of the present study is to evaluate the long-term effect of acarbose in reducing hypoglycemic symptoms and influencing laboratory measurements in patients with the diagnosis of reactive hypoglycemia. Design and Methods: 21 non-obese (BMI <27 kg/m2) patients (6 males, 15 females) complaining of postprandial symptoms suggesting hypoglycemia and who showed blood glucose values of <54 mg/dI on one or more occasions during a 5 h oral glucose tolerance test (OGTT) were selected. Results: Before treatment, ingestion of glucose decreased plasma glucose levels at the 3rd and 4th hours, the lowest levels being 39 mg/dl and 45 mg/dl respectively. Eighteen patients had hypoglycemic symptoms during OGTT. Following 3 months of acarbose treatment, the lowest plasma glucose levels at the 3rd and 4th hours increased to 67 mg/dI and 75 mg/dI respectively. Plasma insulin and c-peptide levels were reduced between the 1st and 5th hours, but only the 1st and 2nd hour decrements were statistically significant. The area under the curve (AUC) between 0–300 minutes for insulin was not significant. Plasma glucose levels were significantly increased during the last 3 hours The AUC for glucose was not significantly changed. Frequency of hypoglycemic attacks was reduced from 4 times a week to 1. C-peptide levels in 24-hour urine collection did not change significantly: 45 μg/I and 56 μg/I respectively before and after treatment. Conclusions: These results confirm that acarbose may be of value in preventing reactive hypoglycemia by reducing the early hyperglycemic stimulus to insulin secretion, and in the treatment of reactive hypoglycemia.


Clinical Rheumatology | 2001

Hypothalamus-Hypophysis-Thyroid Axis, Triidothyronine and Antithyroid Antibodies in Patients with Primary and Secondary Sjo¨gren’s Syndrome

A. Gökhan Özgen; Gokhan Keser; Nihal Erdem; Kenan Aksu; Gürbu¨z Gümüsdis; Taylan Kabalak; Eker Doganavsargil

Abstract: It has been well established that, anti-thyroglobulin antibodies (ATG) and anti-microsomal antibodies (AMC) may be present in various thyroid disorders and other systemic autoimmune diseases, including Sjo¨gren’s syndrome (SS). However, presence of circulating autoantibodies to thyroid hormones, i.e. both to triiodothyronine (T3) and tetraiodothyronine (T4), has not been studied extensively in SS. Autoantibodies to T3 and T4 are very important, because serum T3 and T4 levels may be detected spuriously higher or lower, due to the presence of these autoantibodies. Their presence should be suspected when measured serum thyroid hormone levels are not consistent with clinical status of the patient. SS is a slowly progressive, inflammatory autoimmune disease, affecting primarily the exocrine glands. Thyroid gland, being a target in some autoimmune diseases, is well known to be affected in SS as well. Keeping this possibility in mind, we investigated T3 autoantibody levels and thyroid gland involvement in patients with SS.  Twenty-six SS patients (F/M:22/4) with a mean age of 46,6 years, were recruited in this study.Twelve of them were accepted as primary SS (pSS), while others had secondary SS (sSS) (7 with rheumatoid arthritis (RA), 3 with systemic lupus erythematosus (SLE), 3 with progressive systemic sclerosis (PSS) and 1 with sarcoidosis). Thyroid function tests, including T3, T4, fT3, fT4, TSH, ATG, AMC, T3 antibody measurements, thyroid scintigraphy, thyroid ultrasonography and TRH stimulation tests were performed in all patients. We compared our results with those of the twenty healthy normal controls.  Serum ATG and/or AMC were detected in three patients with pSS (25%) and no patients with sSS. No significant difference could be shown in the other parameters, including T3 autoantibodies and thyroid function tests. TRH stimulation test was also normal, showing that the hypothalamus-hypophysis-thyroid axis was not affected in patients both with pSS and sSS.  In conclusion, we found that T3 autoantibody levels in pSS, were not significantly higher than sSS and normal controls.


Journal of Assisted Reproduction and Genetics | 2009

Apolipoprotein E gene polymorphism and polycystic ovary syndrome patients in Western Anatolia, Turkey

Sevki Cetinkalp; Muammer Karadeniz; Mehmet Erdogan; Ayhan Zengi; Vildan Bozok Çetintaş; Asli Tetik; Zuhal Eroglu; Buket Kosova; A. Gökhan Özgen; Fusun Saygili; Candeger Yilmaz

PurposeDyslipidemia, cardiovascular disease and hypertension are more frequently seen in patients with PCOS than in normal patients. We aimed at evaluating the distribution of Apo E alleles that can influence cardiovascular risk of the PCOS patients and control subjects.MethodsIn this study, 129 young women with PCOS and 91 healthy women were included. In all subjects we performed hormonal, biochemical and Apo E genetic analysis.ResultsThe Apo E3 allele was found at a significantly higher frequency in the PCOS patient group compared with the control group. The Apo E2 allele was found at a significantly higher frequency in the control group compared with the patient group with PCOS.ConclusionsAlthough there were genotype and allele differences between control and patient groups in this study, no statistically significant change was determined in lipid and other cardiovascular risk factors in connection with allele and genotype.


Advances in Therapy | 2008

Prolactin levels and examination with breast ultrasound or mammography

Fulden Sarac; Pelin Tutuncuoglu; A. Gökhan Özgen; Fusun Saygili; Candeger Yilmaz; Işil Bilgen; Aşsenur Memiş

ObjectiveStresses including surgery, exercise, nipple stimulation, and chest wall injury such as mechanical trauma, burns, surgery, herpes zoster of thoracic dermatomes, hypoglycaemia and acute myocardial infarction cause significant elevation of prolactin levels. The aim of the present study was to evaluate the changes in prolactin level during mammography and ultrasonographic examination. Materials and Methods: Seventy-four premenopausal (mean age, 32.1±7.3 y) and 81 post-menopausal women (mean age, 48.3±8.9 y) were enrolled into the study. Premenopausal women were evaluated with ultrasound (Senographe 600 T [General Electric]) and post-menopausal women were examined with mammography (Mammomat 3000 [Siemens]). Blood samples for prolactin were taken prior to ultrasound or mammography and 15, 30 and 45 min after ultrasound or mammography. Results: Mean baseline serum prolactin level was 7.2±0.9 ng/ml in premenopausal women before ultrasound. Mean baseline serum prolactin level was 5.4±0.4 ng/ml in post-menopausal women before mammography. It was found that there were no significant changes in prolactin levels after ultrasound or mammography (P>0.05). Mean levels of baseline prolactin were statistically significant higher in premenopausal than in post-menopausal women (P=0.03). Conclusion: Mammography and ultrasonographic examination have no acute effect on serum prolactin levels in either group. There is no need to wait before measuring the prolactin level after mammographic or ultrasonographic breast examination.


Endocrine Practice | 1999

Triiodothyronine antibodies in patients with goiter.

A. Gökhan Özgen; Taylan Kabalak; Füsun Hamulu; Firat Bayraktar; Candeger Yilmaz; Enis Yetkin; Mehmet Tüzün

OBJECTIVE To investigate the prevalence of triiodothyronine (T(3)) antibodies in patients with goiter, the influence of these antibodies on the results of thyroid hormone measurements, and the potential relationship between T(3) antibodies and thyroid autoantibodies. METHODS We undertook a study of 100 healthy control subjects (80 female and 20 male subjects) who had no clinical or biochemical evidence of thyroid disease and 100 patients (81 female and 19 male patients) with goiter. Serum concentrations of total T(3), total thyroxine, free T(3), and free thyroxine were measured by radioimmunoassay kits with a coated tube method. An immunoprecipitation method was used to detect anti-triiodothyronine auto-antibodies. RESULTS Patients with a T(3) antibody binding ratio +3 standard deviations (SD) above the mean for the normal control group were considered to have T(3) antibodies. Normal control group binding was 2.4 +/- 1.3%. On the basis of +3 SD, seven patients had T(3) antibodies. The mean serum total T(3) level was 1.61 +/- 0.1 nmol/L in patients with binding ratios above +3 SD, whereas the mean serum total T(3) level was 2.23 +/- 0.3 nmol/L in patients without T(3) antibodies. Thus, patients with a binding ratio above +3 SD had a significant decrement in total T(3) levels. No correlation was found between the presence of T(3) antibody and antimicrosomal and antithyroglobulin antibodies. CONCLUSION When serum thyroid hormone concentrations are measured with a coated tube-radioimmunoassay method, antibodies can result in low T(3) concentrations. T(3) antibodies should be suspected whenever a discordance is noted between the measured thyroid hormone concentrations and the clinical status.


Pathology Research and Practice | 2001

Small Cell Neuroendocrine Carcinoma of the Thymus Complicated by Cushing's Syndrome: Report of a 58-year-old Woman with a 3-year History of Hypertension

Mine Hekimgil; Füsun Hamulu; Ufuk Çağırıcı; Bulent Karabulut; A. Gökhan Özgen; Saliha Soydan; Candeger Yilmaz

A 58-year-old woman with a history of Cushings syndrome for three years presented with a mediastinal mass and received the diagnosis of small cell neuroendocrine carcinoma of the thymus invading the pericardium. On immunohistochemical study, the neoplastic cells reacted with antibodies against cytokeratin, epithelial membrane antigen, neuron-specific enolase, chromogranin, synaptophysin, and ACTH. Clinicopathologic findings of this rare case of ectopic adrenocorticotropic hormone (ACTH) syndrome are discussed with a literature review.


Journal of Endocrinological Investigation | 2010

Thermogenic response and leptin levels rise after recovery of the euthyroid state

Fulden Sarac; A. Gökhan Özgen; Gürbüz Çelebi; Murat Pehlivan; H. Uluer; C. Yilmaz

Objective: The aims of the study were to compare: a) the thermogenic responses in subclinical hypothyroidism (SH) and euthyroid state; b) the relationship between thermogenic response and leptin level. Methods: Thirty women diagnosed with SH (mean age 39.9±4.1 yr; body mass index 23.2±2.5 kg/m2) were enrolled in the study. Thyroid function tests, leptin, and lipid profiles were measured during SH and after stable euthyroidism was recovered. Thermogenic response was measured by Water Immersion Calorimetry during SH and after the euthyroid state was attained. Results: The mean level of thermogenic response was found to be 1.45±0.43 kcal/kg.h in women with SH. It changed to 1.54±0.77 kcal/kg.h (p=0.01) in the euthyroid state; the change was statistically significant. Mean level of leptin was found to be 7.22±2.6 ng/ml in SH; and 15.8±8.0 ng/ml in the euthyroid state. There was a positive correlation between leptin and free T3 (r=0.460, p=0.009) levels in SH. There were positive correlations between leptin level and fat mass in SH (r=0.820, p=0.01) and in the euthyroid state (r=0.700, p=0.03). Conclusions: No correlations were found between thermogenic response and leptin levels in SH and in the euthyroid state. Thermogenic response and leptin levels rose after the euthyroid state was recovered.


Thyroid | 1999

Evaluation of routine basal serum calcitonin measurement for early diagnosis of medullary thyroid carcinoma in seven hundred seventy-three patients with nodular goiter.

A. Gökhan Özgen; Füsun Hamulu; Firat Bayraktar; C. Yilmaz; Mehmet Tüzün; Enis Yetkin; Muge Tuncyurek; Taylan Kabalak


Endocrine Journal | 2005

Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease.

Didem Dereli; Tuğrul Dereli; Firat Bayraktar; A. Gökhan Özgen; Candeger Yilmaz

Collaboration


Dive into the A. Gökhan Özgen's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge